Kestra Reports Q1 Fiscal 2027 Earnings with Strong Revenue Growth
Kestra Medical Technologies (KMTS) reported a significant revenue increase of $31.0 million for the first quarter of fiscal year 2027, marking a 60% growth compared to the previous year. This was driven by expansion in its wearable cardioverter defibrillator market and an increased share of in-network patients. The company also raised its full-year revenue guidance from $137 million to $141 million, projecting continued strong performance with expected annual growth of 48%. Kestra's gross margin reached 56.5%, up over 10 percentage points year-over-year due to volume leverage and cost improvements. However, GAAP operating expenses rose significantly to $55.2 million from $37.7 million in the prior period as a result of commercial expansion and R&D investments. Despite this, Kestra maintains strong liquidity with total assets amounting to $320 million.
Tickers: $KMTS
Topics: gross_margin_improvement guidance_update liquidity operating_expenses revenue_growth